Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Inclusion Criteria

A patient will be eligible for inclusion in this study only if all of the following criteria are met:

• Patients must have a histologically confirmed diagnosis of Ewing's sarcoma, PEComa, epithelioid sarcoma, desmoid tumor, chordoma, non-small cell lung cancer, small cell lung cancer, urothelial carcinoma, melanoma, renal cell carcinoma, squamous cell carcinoma of head and neck, hepatocellular carcinoma, classical Hodgkin's lymphoma, MSI-H/dMMR metastatic colorectal cancer, and tumors with genetic mutations sensitive to mTOR inhibitors, that is either metastatic or locally advanced and for which surgery is not a recommended option.
• Patients must have one or more measurable target lesions by CT scan or MRI. Measurable disease by RECIST v1.1.
• Patients must not have been previously treated with a PD-1 inhibitor in combination with an mTOR inhibitor.
• Prior treatment (investigational or other), chemotherapy, radiotherapy, surgery, or other therapeutic agents (except immunotherapy and mTOR inhibitors) is allowed, if completed after 5 half-lives or ≥28 days prior to enrollment, whichever is shorter.
• Eligible patients, 12 years or older, with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
• Patients must have the following blood chemistry levels at screening (obtained ≤14 days prior to enrollment (local laboratory):
• total bilirubin ≤1.5 x upper limit of normal (ULN) mg/dl
• Aspartate aminotransferase (AST) ≤2.5 x ULN (≤5 x ULN if attributable to liver metastases)
• serum creatinine ≤1.5 x ULN
• Adequate biological parameters as demonstrated by the following blood counts at screening (obtained ≤14 days prior to enrollment, local laboratory):
• Absolute neutrophil count (ANC) ≥1.5 × 109/L;
• Platelet count ≥100,000/mm3 (100 × 109/L);
• Hemoglobin ≥9 g/dL.
• Serum triglyceride 3 months, as determined by the investigator.
• Ability to understand and sign informed consent.
• Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures.

Exclusion Criteria

A patient will not be eligible for inclusion in this study if any of the following criteria apply:

• Concurrent or prior immunotherapy with a PD-1 inhibitor in combination with an mTOR inhibitor.
• Known active uncontrolled or symptomatic central nervous system (CNS) metastases. A patient with controlled and asymptomatic CNS metastases may participate in this study. As such, the patient must have completed any prior treatment for CNS metastases ≥28 days (including radiotherapy and/or surgery) prior to start of treatment in this study and should not be receiving chronic corticosteroid therapy for the CNS metastases.
• Active gastrointestinal bleeding.
• Pre-existing thyroid abnormality is allowed provided thyroid function can be controlled with medication.
• Uncontrolled serious medical or psychiatric illness. Patients with a "currently active" second malignancy other than non-melanoma skin cancers, carcinoma in situ of the cervix, resected incidental prostate cancer (staged pT2 with Gleason Score ≤ 6 and postoperative prostate-specific antigen (PSA) 8% despite adequate therapy.
• Unstable coronary artery disease or myocardial infarction during preceding 6 months.
• Receiving any concomitant antitumor therapy.
• Patients with history of interstitial lung disease and/or pneumonitis, or pulmonary hypertension.
• Use of strong inhibitors and inducers of CYP3A4 within the 14 days prior to receiving the first dose of ABI-009. Additionally, use of any known CYP3A4 substrates with narrow therapeutic window (such as fentanyl, alfentanil, astemizole, cisapride, dihydroergotamine, pimozide, quinidine, terfenadine) within the 14 days prior to receiving the first dose of ABI-009.
• Known Human Immunodeficiency Virus (HIV).
• Active Hepatitis B or Hepatitis C.
• Non-oncology vaccine therapy used for prevention of infectious disease within 4 weeks of trial enrollment

16